glp-1 agonist fda approval FORMULATION DEVELOPMENT 💊New GLP-1 pill gets FDA

This is a kind of end-product inhibition that prevents the GSH concentration from rising too high

CLINICAL PHARMACOLOGY : Mechanism of Action : Liraglutide is an acylated human Glucagon-Like Peptide-1 (GLP-1) receptor agonist with 97% amino acid sequence homology to endogenous human GLP-1(7-37)

Anecdotal/observational reports (body composition, energy, recovery) exist in performance settings, but lack standardized dosing, controls, and validated endpoints

Patients with type 2 diabetes require careful planning to maintain glycaemic control if GLP-1 therapy is adjusted, with typical perioperative glucose targets of 6-10 mmol/L